Direct oral anticoagulants provide an alternative to vitamin K antagonists for the anticoagulation therapy in atrial fibrillation (AF). The availability of several treatment options with different attributes makes shared decision-making appropriate for the choice of anticoagulation therapy. The aim of this study was to understand how physicians choose an oral anticoagulant (OAC) for patients with AF and how physicians view patients' participation in this decision. Semi-structured interviews with 17 Finnish physicians (eight general practitioners and nine specialists) working in the public sector were conducted. An interview guide on experience, prescribing and opinions about oral anticoagulants was developed based on previous literature. The data were thematically analysed using deductive and inductive approaches. Based on the interviews, patient's opinion was the most influential factor in decision-making when there were no clinical factors limiting the choice between OACs. Of patient's preferences, the most important was the attitude towards co-payments of OACs. Patients' opinions on monitoring of treatment, dosing and antidote availability were also mentioned by the interviewees. The choice of an OAC in AF was patient-centred as all interviewees expressed that patient's opinion affects the choice.
anticoagulation therapy in AF, direct oral anticoagulants (DOACs) rivaroxaban, dabigatran, apixaban and edoxaban now provide an alternative. [3] [4] [5] [6] In fact, current European guidelines recommend the use of DOACs for eligible AF patients in preference to VKAs. 1 Besides their fixed dosing without the need of regular laboratory monitoring, DOACs have a favourable risk-benefit profile, including a lower risk of intracranial haemorrhage, compared to warfarin. 7 The European guidelines on management of AF recommend considering patients' preferences when making treatment decisions about, for example, medications. 1 In shared decision-making, patients' preferences are taken into account, and the treatment decision is consensual between the patient and the physician. 8 Shared decision-making is considered appropriate for stroke prevention in AF because of the availability of several treatment options with different risk-benefit profiles. Recent physician surveys and interviews suggest that physicians consider patient participation in decision-making on the use of oral anticoagulants (OACs) in AF important. [9] [10] [11] [12] Physicians also report clinical characteristics of the patient, 13 risk of adverse events, 11 their own knowledge, experience 10 and preferences 14 to be important in decision-making. Database studies have identified mainly clinical factors, such as estimated stroke risk, 15, 16 age [16] [17] [18] [19] and other cardiovascular diseases 16, 17, [19] [20] [21] as factors affecting the choice of an OAC. These studies have also found lower socio-economic status [18] [19] [20] and poorer medication coverage 15, 21 to favour the use of VKAs.
There is no information on how patients participate in the decision-making on OACs in Finland where the setting is different to many other countries. For example, the Finnish guidelines do not prefer use of DOACs over VKAs but in most cases recommend patient-specific selection between the types of OACs. 22 We conducted a qualitative study among Finnish physicians in primary and specialized health care working in the public sector to better understand the factors affecting physicians' choice of an OAC in AF after the treatment decision has been made. We have previously reported results on the effect of clinical and non-clinical factors (eg need of cardioversion, contraindications, renal function, co-payments) on the choice of an OAC. 23 In this paper, we focus on the participation of patients in this choice as perceived by physicians.
| METHODS

| Context
In Finland, the current clinical guidelines recommend patient-specific selection between warfarin (the only VKA available in Finland) and DOACs in AF to be based on the evaluation of medications' properties and the patient's opinion. 22 DOACs are preferred if anticoagulation is needed only for short-term (eg for cardioversion). Among the disadvantages of DOACs, the guideline lists the lack of a specific antidote for other DOACs than dabigatran. Also, the cost of DOACs is among the disadvantages. At the time of the interviews (November 2016-February 2017), the difference in the monthly cost shared by the patient between warfarin and DOACs was nearly €50 (only small cost differences between DOACs). In addition, not all patients with AF were entitled to the reimbursement for DOACs, increasing the difference to almost €90. The quality of warfarin treatment, measured as time in therapeutic range, has been reported to be good in Finland compared to many non-Nordic countries. 24, 25 In addition to the regulatory monitoring of pharmaceutical marketing, the pharmaceutical industry self-regulates its marketing in Finland. 26 It is forbidden to offer physicians any financial incentives, including promotional gifts related to prescription-only medications. Training and medical representations by the pharmaceutical industry are also regulated. No incentives for prescribing certain medications or managing chronic illnesses are offered by the public healthcare system either.
| Sampling, recruitment and data collection
Using purposive sampling, we recruited participants from 12 primary healthcare organizers with and without anticoagulation clinics and 13 clinics in six special healthcare hospitals in Central and Eastern Finland. Physicians were recruited by email personally or through administration, chief physicians, medical directors or contact persons named by the organizations. Recruitment continued until data saturation 27 (ie after no new themes emerged in interviews). The study included physicians who were working in primary or specialized health care (cardiology, neurology and internal medicine) in the public sector and were willing to participate in the study. The three medical specialties were chosen because they typically treat patients with AF. Data were collected through semi-structured interviews. 28 We developed an interview guide with open-ended questions based on previous literature 9,10,12-14 (Appendix S1). The guide was pretested in three pilot interviews that were not included in the data. The interviewer also asked follow-up questions prompted by participant's responses, and points outside the guide were discussed if introduced by the participant. Interviews were recorded with participants' permission and transcribed verbatim by an independent transcription service. One researcher (EA) conducted all interviews. In total, 13 face-to-face interviews at physicians' work places and four phone interviews (25-65 min each) were conducted. The sample included eight general practitioners (GPs) from seven primary healthcare organizers and nine specialists (two from neurology, five from cardiology and two from internal medicine) from six hospitals ( Table 1) . Three GPs worked in an organization with an anticoagulation clinic.
The interviewees had practiced medicine from less than a year to >30 years (Table 1 ). In addition, the extent of experience with DOACs varied across the physicians from writing only a few DOAC prescriptions to prescribing them weekly. At the time of the interviews, none of the interviewees had prescribed edoxaban.
| Data analysis
One researcher (EA) compared the transcripts of the interviews with the recordings and analysed de-identified data to find factors affecting the choice of an OAC. The data were thematically analysed using both deductive and inductive approaches. 29 In deductive approach, factors previously reported to affect the choice were looked for in the data (eg co-payment, monitoring and patients' preferences). In inductive approach, the data were searched to find new influential factors. The new factors found inductively included indication (the need for cardioversion in particular), physicians' past OAC prescribing habits, characteristics of clinical trials and patients' entitlement to reimbursement affecting the amount of co-payment.
| Ethics and consent statement
The study complied with the national ethical principles of research. 30 According to the instructions, this study did not require ethical approval. Willingness to participate in the interviews was seen as a consent to participate in the study.
| RESULTS
Based on the interviews, when there were no contraindications or other clinical factors limiting the choice between OACs (eg renal function, interactions with co-medication), patient's opinion was the most influential factor. There were no great differences between the interviewed GPs and specialists in the effect of patients' preferences on the decision-making, overall, and all the interviewees expressed that patients' opinions affect the choice. When physicians were asked generally about prescribing of OACs and the process of choosing an OAC, all but two physicians mentioned patient participation in the decisionmaking unprompted. In addition, when asked which factors ease the choice between OACs, six physicians mentioned patients' opinion.
"Perhaps you do to steer the conversation into a specific direction. Even if there aren't any contraindications, there are still arguments that support one way over the other. Well, there's the 40-year-old relatively healthy man who has no risk of bleeding. In that case, the patient gets to choose whether he wants to take medication once or twice a day." (S04, cardiology)
Of patients' preferences, the most important was their views about the co-payment of OACs (Table 2 ). All the interviewees said that DOACs are too expensive for some patients for whom the co-payment is the deciding factor. Even though some of the interviewees had strong preferences for DOACs, they prescribed warfarin if the patient considered DOACs too expensive. 
Patients' attitude towards the monitoring of warfarin treatment was mentioned in ten interviews (Table 2) . According to the interviewees, some patients want to use DOACs because they find regular monitoring of international normalized ratio (INR) inconvenient. Patients may Besides preferences affecting the choice between warfarin and DOACs, some interviewees mentioned patients' preferences that can affect the choice between different DOACs (Table 2) . Ten interviewees said they took into account patients' opinion about the dosing frequency (ie taken once or twice a day). In addition, six interviewees told patients may wish to be prescribed a DOAC with a specific antidote available. However, there were differences between the interviewees whether they offered all DOACs to patients or chose which DOAC to offer alongside warfarin.
"Some go for [a medication taken] once a day. Then again, some opt specifically for a medication with an existing antidote." (S03, neurology)
Based on the interviews, the most common reason why physicians included patients in the decision-making was the large difference in the co-payments between warfarin and DOACs. All interviewees mentioned the importance of co-payment to some patients, and a few physicians mentioned specifically that they prescribe each patient an OAC the patient can afford to use. In addition, three physicians felt that patients adhere better to their treatment when they have participated in the decision-making.
Another reason why patient preferences are so influential might be that the different OACs were viewed equally effective: 11 physicians considered high-quality warfarin treatment as effective as DOACs, although 11 physicians felt DOACs to be safer than warfarin. In addition, 10 physicians mentioned that they did not see great differences between different DOACs or that they have not been directly compared and, therefore, none of them can be said to be better than the others. However, some physicians expressed they preferred a specific anticoagulant in some situations and in those cases they tried to steer the conversation towards their choice or offer only one or some of the DOACs to the patient.
Even though our main focus was on the initiation of OAC treatment, the interviewees were also asked about switching of OACs. The influence of patients' opinions was evident also in these responses: the most frequently reported reasons for switching were patient request in addition to poor quality of warfarin therapy. Thirteen physicians told that they had switched patients from warfarin to a DOAC because patients, for example, found DOACs easier to administer or INR monitoring inconvenient (Table 2 ). Seven interviewees had switched patients from a DOAC to warfarin, mainly due to the high co-payment of DOACs.
| DISCUSSION
Based on the 17 interviews conducted in our study, the choice of an OAC in AF is patient-centred, particularly when choosing between warfarin and a DOAC, and the patient's preferences strongly affect the decision-making if there are no contraindications or other clinical factors limiting the choice. According to the interviewed physicians, warfarin's markedly lower co-payment is a deciding factor for some patients. In addition, patients may have preferences regarding the dosing frequency or availability of a specific antidote regarding DOACs. The main reason for physicians to involve the patient in the decision-making seems to be to enhance treatment success.
Our findings on the importance of patients' opinions accord with recent studies on decision-making on anticoagulation therapy in AF. In their study, Kirley et al 10 interviewed physicians about decision-making on anticoagulation management in patients with AF in general. Patient convenience and preferences were found to be important to physicians when considering anticoagulation. In addition, co-payment emerged as an important barrier to DOAC use. In another US study, physicians from a single medical centre were surveyed about factors influencing their choice between warfarin and dabigatran for patients
Preferences n
When initiating treatment
Co-payments 17
Need for treatment monitoring 10
Dosing 10
Availability of an antidote 6
When switching treatment Co-payments 7
Need for treatment monitoring 4
Convenience of treatment 4
with AF. 13 Patient request was the third most common reason, after factors related to patient convenience, to prescribe dabigatran to patients without a previous OAC and the fourth most common reason among patients using warfarin after factors related to patient convenience and unstable INR. The co-payment of DOACs was important also in this study as cost was the most common reason for not prescribing dabigatran. Similar results about the importance of the patient's role have been reported also from other countries. In a Canadian survey for internal medicine residents, patient convenience was the second most important factor when choosing an OAC for patients with AF after adverse events. 11 In Italy, 70% of internal medicine centres participating in a survey on DOACs regarded the patient's preference to be highly relevant when prescribing DOAC therapy in AF. 9 In a Norwegian focus group study among hospital physicians, patients' preferences were reported to be important factors in decision-making although patients' characteristics were most influential factors when choosing an OAC. 12 Palacio et al 31 reported that patients potentially exposed to a decision on anticoagulation (ie patients at risk of AF or already on OACs) prefer to take part in the decision-making. This accords with the patients' participation described by the physicians interviewed in our study. However, in the survey by Choi et al., only 25% of warfarin users and 37% of dabigatran users had discussed with their physician about treatment options when initiating anticoagulation. 32 The preceding study was conducted in 2011. It is possible that patients' participation in decision-making on OACs has increased after more DOACs have entered the market and DOAC use has increased. Results from patient-based studies support our observations on the importance of OAC attributes other than the effect on stroke and bleeding risks. According to the review by Wilke et al., patients prefer more easily administered treatments if the treatments' clinical effects are similar. 33 For example, in a German study, patients overall preferred a treatment with no requirement for INR monitoring or dose adjustments, no interactions with food and once-daily dosing. 34 In a Dutch study, the most important reason for patients to switch to a DOAC was that frequent laboratory monitoring is not required. 35 However, the results on patient preferences have been mixed. 36 For example, patients' attitudes towards monitoring may vary considerably, 37 and some patients using warfarin are reluctant to switch to a DOAC because the lack of laboratory monitoring. 38 This accords with our interviews where physicians mentioned both patients' negative and positive attitudes towards INR monitoring. In an Italian study of VKA users, the majority was worried about using a DOAC for which no antidote was available. 38 Accordingly, some of our interviewees brought up the importance of the availability of a specific antidote for some patients. As DOACs' reimbursement rates have been raised in Finland after our study period causing the difference in co-payments to decrease for patients entitled to reimbursement, 39 it is possible that the importance of these OAC attributes has increased in decision-making. Patients' differing preferences reported in previous studies [36] [37] [38] and in our study emphasize the importance of shared decision-making when choosing an OAC. As different patients have different preferences, physicians should ask their patients which attributes are important to them. Application of shared decision-making could improve patient adherence to treatment. 40 Our study has limitations. Firstly, the number of interviewed physicians is small. However, our sample size is similar to that of previous qualitative studies (range 7 to 12 interviewees 10, 12 ). Furthermore, data saturation was reached. Conversely, although we reached theme saturation, we did not reach meaning saturation in all the themes emerging in the interviews. 27 For example, there was not enough evidence to draw conclusions on the association between physicians' prescribing frequency and shared decision-making. Larger and quantitative studies are needed to explore this and the generalizability of the results to physicians in Finland and elsewhere. Secondly, we did not conduct any interviews among patients with AF to ascertain their participation in the decision-making about OACs. Further studies are needed to study whether patients feel that their preferences are taken into account by their physicians and whether this impacts their adherence. Another limitation of our study is that only one researcher analysed the data, although continuous discussions were done among the research group to reflect the findings. According to the views of the interviewed physicians, AF patients participate in the choice of their OAC. The interviewed physicians took into consideration patients' preferences in particular when choosing between warfarin and a DOAC. This was mainly due to the difference in the costs of these medications shared by the patient but also to patients' preferences regarding INR monitoring. When choosing between DOACs, some physicians also took into account patients' preferences on dosing frequency and availability of a specific antidote. The main reason for considering patients' preferences was to enhance the success of treatment.
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